All In Biotech

Drug Trial Radar · NCT00334282

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

A Randomised, Double-blind, Placebo Controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) Compared to Placebo in Patients With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Feb 5, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 435 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

435

Actual

Start

Apr 2006

Primary completion

May 2008

Study completion Dec 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jun 7, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC). Approximately 350-400 eligible patients will be stratified and randomized in a 2:1 ratio to receive either 800 mg pazopanib once daily or matching placebo. The study treatment will continue until patients experience disease progression, unacceptable toxicity or death. Primary objective of the study is to evaluate and compare the two treatment arms for progression-free survival. Principal secondary objective is to evaluate and compare the two treatment arms with respect to overall survival. Other objectives are overall response rate \[complete response (CR) + partial response (PR)\], rate of CR + PR + 6 months stable disease, and the incidence, severity and causality of adverse events and serious adverse events. Safety and efficacy assessments will be regularly performed on all patients. An Independent Data Monitoring Committee will be established to monitor safety during the course of the study and to evaluate interim efficacy data on overall survival.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • PazopanibDrug

    Oral pazopanib tablet 800 mg once daily continuously

  • placeboDrug

    matching placebo (800 mg tablet) once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free SurvivalTime frame: Randomization until progression (up to 2 years)

Locations

99 sites in 25 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Quilmes, Argentina

  • GSK Investigational Site

    San Miguel de Tucumán, Argentina

  • GSK Investigational Site

    Capital Federal, Buenos Aires, Argentina

  • GSK Investigational Site

    Córdoba, Córdoba Province, Argentina

  • GSK Investigational Site

    Rosario, Santa Fe Province, Argentina

  • GSK Investigational Site

    St Leonards, New South Wales, Australia

  • GSK Investigational Site

    Waratah, New South Wales, Australia

  • GSK Investigational Site

    Hobart, Tasmania, Australia

  • GSK Investigational Site

    Heidelberg, Victoria, Australia

  • GSK Investigational Site

    Wodonga, Victoria, Australia

  • GSK Investigational Site

    Salzburg, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Vienna, Austria

  • GSK Investigational Site

    Belo Horizonte, Minas Gerais, Brazil

  • GSK Investigational Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • GSK Investigational Site

    Jaú, São Paulo, Brazil

  • GSK Investigational Site

    Santiago, Región Metro de Santiago, Chile

  • GSK Investigational Site

    Santiago, Región Metro de Santiago, Chile

  • GSK Investigational Site

    Viña del Mar, Valparaiso, Chile

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    Chomutov, Czechia

  • GSK Investigational Site

    Ostrava - Poruba, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tartu, Estonia

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Athens, Greece

  • GSK Investigational Site

    Pátrai, Greece

  • GSK Investigational Site

    Thessaloniki, Greece

  • GSK Investigational Site

    Hong Kong, Hong Kong

  • GSK Investigational Site

    Kowloon, Hong Kong

  • GSK Investigational Site

    Tuen Mun, New Territories, Hong Kong

  • GSK Investigational Site

    Bangalore, India

  • GSK Investigational Site

    Hyderabad, India

  • GSK Investigational Site

    Mumbai, India

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.